Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning

NCT ID: NCT05624736

Last Updated: 2022-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-20

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a restrospective study to establish a deep learning model based on multi-parametric magnetic resonance imaging scans to predict Grade, histopathologic type and genotype of adult diffuse Glioma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glioma is a common kind of tumor in central nervous system. The pre-operative prediction of grade, histopathologic type and genotype is important for treatment and management of Adult diffuse Glioma patients. Right now, most of the diagnostic prediction models on glioma are based on 2016 WHO central nervous system tumor guideline. The goal of this study is to establish a new deep learning model to predict Grade, histopathologic type and genotype of adult diffuse Glioma. We will recruit 500 patients with pathologically confirmed diagnosis of Glioblastoma, Astrocytoma and Oligodendroglioma who received neurologic surgery in our center. Each subject underwent pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI. Pathologic diagnosis of each patient are available in pathology department. A deep learning based hierarchical diagnosis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Astrocytoma Glioblastoma Multiforme Oligodendroglioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glioblastoma Group

Patients with the diagnosis of Glioblastoma based on 2021 WHO central nervous system tumor guideline.

multi-parametric magnetic resonance imaging scan

Intervention Type DIAGNOSTIC_TEST

Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Pathology examination

Intervention Type DIAGNOSTIC_TEST

The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Astrocytoma Group

Patients with the diagnosis of Astrocytoma based on 2021 WHO central nervous system tumor guideline.

multi-parametric magnetic resonance imaging scan

Intervention Type DIAGNOSTIC_TEST

Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Pathology examination

Intervention Type DIAGNOSTIC_TEST

The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Oligodendroglioma Group

Patients with the diagnosis of Oligodengroglioma based on 2021 WHO central nervous system tumor guideline.

multi-parametric magnetic resonance imaging scan

Intervention Type DIAGNOSTIC_TEST

Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Pathology examination

Intervention Type DIAGNOSTIC_TEST

The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

multi-parametric magnetic resonance imaging scan

Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.

Intervention Type DIAGNOSTIC_TEST

Pathology examination

The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients undergoing surgery in Nanjing DrumTower Hospital between 2010.01 and 2022.05 with post-surgery pathological diagnosis of WHO Grade II to IV Adult Diffuse Glioma.
2. Available pre-surgery T1WI, T2WI, T1CE, FLARI and DWI MR sequences
3. No pre-surgery anti-tumor therapy

Exclusion Criteria

1. Poor image quality
2. Failed image preprocessing
3. Unavailable pathology data
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xin Zhang, Master

Role: CONTACT

13814066403

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xin Zhang, Master

Role: primary

13814066403

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-LCYJ-MS-25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.